Second–line chemotherapy for non—small–cell lung cancer
- 1 January 2000
- journal article
- research article
- Published by Springer Nature in Current Oncology Reports
- Vol. 2 (1) , 96-101
- https://doi.org/10.1007/s11912-000-0016-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II TrialCancer Investigation, 1999
- 99 Efficacy and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer (NSCLC)Lung Cancer, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non small cell lung cancer (NSCLC)Lung Cancer, 1994
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?Journal of Clinical Oncology, 1993
- Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.Journal of Clinical Oncology, 1990
- Is chemotherapy for metastatic non-small cell lung cancer "worth it"?Journal of Clinical Oncology, 1990
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988